Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 13Gastrointestinal 4Thoracic 2Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Plasma cell 1Other 1Gynecologic 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 208Multiple Endocrine Neoplasia Type 1 130Thyroid Cancer, Papillary 78Pituitary Neoplasms 70Thyroid Neoplasms 59Pheochromocytoma 55Carcinoma, Neuroendocrine 49Neoplasms 48Carcinoid Tumor 48Carcinoma, Medullary 35Adrenocortical Carcinoma 35Adenocarcinoma, Follicular 34Pancreatic Neoplasms 33Thyroid Carcinoma, Anaplastic 30Neoplasm Metastasis 27Carcinoma, Non-Small-Cell Lung 27Insulinoma 26Breast Neoplasms 25Paraganglioma 24Melanoma 23Colorectal Neoplasms 23Colonic Neoplasms 23Carcinoma, Renal Cell 23Adenoma, Islet Cell 23Somatostatinoma 22Adrenal Gland Neoplasms 22Sarcoma 21Carcinoma, Islet Cell 21Prostatic Neoplasms 20Glucagonoma 19

Interventions

N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sleep Wake Disorders × Endocrine × Clear all
NCT01030939 2017-06-20

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

GlaxoSmithKline

Phase 1 Completed
72 enrolled
Endocrine

Sleep Wake Disorders, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡